Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dasminapant
- Development stage
- Phase 2
- Lead developer
- Ascentage Pharma
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Administration
- Intravenous
01
Overview
APG-1387 (dasminapant) is a small molecule, second mitochondria-derived activator of caspases (SMAC) mimetic that functions as a potent and highly selective inhibitor of apoptosis proteins (IAPs). By antagonizing IAPs, APG-1387 induces apoptosis in cancer cells and modulates immune responses. It has demonstrated antitumor activity in preclinical models and is being investigated for use both as monotherapy and in combination with other agents such as checkpoint inhibitors or chemotherapy. Additionally, APG-1387 has shown potential antiviral activity against hepatitis B virus (HBV), with the ability to induce immune modulation in HBV-infected liver cells. The drug was discovered and developed by Ascentage Pharma.
- Other names
- dasminapantAPG-1387APG1387APG 1387
02
Targets
XIAPBIRC2 (Cellular inhibitor of apoptosis protein 1)IAP (Inhibitor of apoptosis protein family)SMAC
Beyond the preview
Go deeper on dasminapant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dasminapant.